About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

China's National Medical Products Administration granted priority-review approval to Kaixing Life Sciences (Shanghai) Co. for Shurui Jiaolunsai injection, marketed as Kailimei, for CLDN18.2‑positive, HER2‑negative advanced gastric or gastroesophageal

2026-06-22

China's National Medical Products Administration granted priority-review approval to Kaixing Life Sciences (Shanghai) Co. for Shurui Jiaolunsai injection, marketed as Kailimei, for CLDN18.2‑positive, HER2‑negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have progressed after at least two prior lines of therapy. The approval adds a new later‑line treatment option for this biomarker‑defined patient population.

Other News
2026-06-22

The State Council Information Office will hold a press briefing at 15:00 on Monday, June 22, 2026. MOFCOM vice minister and deputy international trade representative Ling Ji, together with officials from the NDRC and the Ministry of Finance, will out

The State Council Information Office will hold a press briefing at 15:00 on Monday, June 22, 2026. MOFCOM vice minister and deputy international trade representative Ling Ji, together with officials from the NDRC and the Ministry of Finance, will outline policy measures to leverage foreign investment to stabilize activity and improve investment quality.
2026-06-22

The Swiss Foreign Ministry welcomes the constructive progress made in the diplomatic negotiations between the mediators, Iran, and the United States.

The Swiss Foreign Ministry welcomes the constructive progress made in the diplomatic negotiations between the mediators, Iran, and the United States.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.